2-溴-1-(4-苯基苯基)丙烷-1-酮 | 73932-64-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-溴-1-(4-苯基苯基)丙烷-1-酮
• 英文名称: 1-(4-biphenylyl)-2-bromo-1-propanone
• 英文别名: biphenyl-4-yl 1-bromoethyl ketone；1-biphenyl-4-yl-2-bromo-propan-1-one；1-Biphenyl-4-yl-2-brom-propan-1-on；(α-Brom-aethyl)-p-xenyl-keton；α-Brom-4-phenyl-propiophenon；4-(α-Brompropionyl)-diphenyl；1-(Biphenyl-4-yl)-2-bromopropan-1-one；2-bromo-1-(4-phenylphenyl)propan-1-one
• CAS: 73932-64-6
• 化学式: C₁₅H₁₃BrO
• mdl: MFCD11182344
• 分子量: 289.172
• InChiKey: LRWLZSXTTFWNTO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.133
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-溴-1-(4-苯基苯基)丙烷-1-酮 以 乙腈 、 苯 为溶剂， 反应 22.0h， 生成 1-([1,1'-biphenyl]-4-yl)propan-1-ol
  参考文献：
  名称：

  4-苯甲酸甲酯与脂肪族叔胺的新型光还原烷基化

  摘要：

  4-苯基苯甲酸甲酯与三乙胺的光致电子转移反应产生氨基酮 (4) 和由氨基酮的 Norrish II 型反应产生的光还原乙基化产物 (2)。

  DOI：

  10.1246/cl.1983.1113
• 作为产物：
  描述：

  4-丙酰联苯 在 溴 作用下， 以 溶剂黄146 为溶剂， 生成 2-溴-1-(4-苯基苯基)丙烷-1-酮
  参考文献：
  名称：

  在芳基α-硒基和芳基α-碲-乙基基酮中通过氧化芳基迁移制备2-芳基丙酸的新方法

  摘要：

  氧化与米kitones的芳基α-phenylseleno -或芳基α-phenyltelluro乙基乙烯缩醛氯过苯甲酸制备通过用二苯基二硒化物，钠或二碲化物二苯基-钠相应的α溴代化合物，分别得到2-羟乙基芳基丙酸酯通过芳基基团迁移以中等至良好的收率。

  DOI：

  10.1039/c39840000426

文献信息

• Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
  申请人：——

  公开号：US20040132788A1

  公开（公告）日：2004-07-08

  The invention relates to thiazole, oxazole, imidazole, isoxazole and isoxazoline derivatives of general formula (I) 1 wherein Het is thiazole, oxazole, imidazole, isoxazole or isoxazoline, n is an integer from 0 to 6, A is notably selected from various optionally substituted aromatic radicals, B is notably hydrogen, alkyl or phenyl, R 1 and R 2 are notably independently hydrogen, alkyl or cycloalkyl and &OHgr; is —NR 46 R 47 or —OR 48 R 46 and R 47 are notably independently hydrogen, alkyl, cycloalkyl or —(CH 2 ) k —COOR 51 , R 51 is notably alkyl or haloalkyl and R 48 is notably hydrogen or alkyl. These compounds have advantageous pharmacological properties which allow their use in therapeutics, notably for treating neurodegenerative disorders or pain.

  本发明涉及噻唑、噁唑、咪唑、异噁唑和异噁唑啉的一般式(I)衍生物，其中Het为噻唑、噁唑、咪唑、异噁唑或异噁唑啉，n为0至6的整数，A特别选自各种可任选取代的芳香族基团，B特别为氢、烷基或苯基，R1和R2特别独立地为氢、烷基或环烷基，Ω为—NR46R47或—OR48，R46和R47特别独立地为氢、烷基、环烷基或—(CH2)k—COOR51，R51特别为烷基或卤代烷基，R48特别为氢或烷基。这些化合物具有有利的药理学特性，使其可用于治疗学，特别是用于治疗神经退行性疾病或疼痛。
• DERIVATIVES OF HETEROCYCLES WITH 5 MEMBERS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
  申请人：CHABRIER DE LASSAUNIERE Pierre-Etienne

  公开号：US20110172434A1

  公开（公告）日：2011-07-14

  The invention relates to thiazole, oxazole, imidazole, isoxazole and isoxazoline derivatives of general formula (I) wherein Het is thiazole, oxazole, imidazole, isoxazole or isoxazoline, n is an integer from 0 to 6, A is notably selected from various optionally substituted aromatic radicals, B is notably hydrogen, alkyl or phenyl, R 1 and R 2 are notably independently hydrogen, alkyl or cycloalkyl and Ω is —NR 46 R 47 or —OR 48 , R 46 and R 47 are notably independently hydrogen, alkyl, cycloalkyl or —(CH 2 ) k —COOR 51 , R 51 is notably alkyl or haloalkyl and R 48 is notably hydrogen or alkyl. These compounds have advantageous pharmacological properties which allow their use in therapeutics, notably for treating neurodegenerative disorders or pain.

  本发明涉及通式（I）的噻唑，噁唑，咪唑，异噁唑和异噁唑啉衍生物，其中Het为噻唑，噁唑，咪唑，异噁唑或异噁唑啉，n为0至6的整数，A特别选择自各种可选取代的芳香基团，B特别为氢，烷基或苯基，R1和R2特别独立地为氢，烷基或环烷基，Ω为—NR46R47或—OR48，R46和R47特别独立地为氢，烷基，环烷基或—(CH2)k—COOR51，R51特别为烷基或卤代烷基，R48特别为氢或烷基。这些化合物具有有利的药理学性质，可以在治疗中使用，特别用于治疗神经退行性疾病或疼痛。
• Catalytic Enantioselective Nucleophilic α-Chlorination of Ketones with NaCl
  作者：Zhiyang Li、Baocheng Wang、Chaoshen Zhang、Wai Yam Lo、Liangliang Yang、Jianwei Sun

  DOI：10.1021/jacs.3c12826

  日期：2024.1.31

  formation with high efficiency and excellent enantioselectivity under mild conditions. The sulfonium motif plays a crucial triple role by permitting smooth dynamic kinetic resolution to take place via a chiral anion binding mechanism in a well-designed phase-transfer system. This protocol represents a new general platform for the asymmetric nucleophilic α-functionalization of carbonyl compounds.

  酮的催化对映选择性α-氯化是非常理想的过程。与采用腐蚀性亲电氯化试剂的常规方法不同，本文公开的方法采用亲核氯化物、氯化钠水溶液，甚至海水作为绿色廉价的氯源。这种机械上不同且电子上相反的方法可以轻松获得多种高度对映体富集的无环 α-氯酮，而传统方法则不太简单。在手性硫脲催化剂的作用下，一系列外消旋α-酮锍盐在温和条件下以高效率和优异的对映选择性形成对映体碳-氯键。锍基序发挥着至关重要的三重作用，在精心设计的相转移系统中通过手性阴离子结合机制实现平稳的动态动力学解析。该协议代表了羰基化合物不对称亲核 α-功能化的新通用平台。
• Process for preparing alpha-aromatic group substituted alkanoic acids or esters thereof
  申请人：SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED

  公开号：EP0048136A2

  公开（公告）日：1982-03-24

  A process for preparing an alpha-aromatic group substituted alkanoic acid or its ester of the general formula wherein Ar represents an aromatic group and R' represents a hydrogen atom or a saturated aliphatic group, or Ar and R1 may form a condensed ring together with the carbon atom to which they are bonded; and R2 represents a hydrogen atom, an alkyl group, or a hydroxyalkyl group. characterized in that an alpha-sulfonyloxyketone acetal of the general formula wherein R3 and R4, independently from each other, represent an alkyl group, or taken together, represent an alkylene group; R5 represents a substituted or unsubstituted alkyl group or an aromatic group; and Ar and R1 are as defined above, is hydrolyzed, or treated with an agent having affinity for oxygen: and novel intermediate compounds of the general formula (II) used in aforesaid process.

  一种通式为α-芳香族取代的烷酸或其酯的制备方法 其中 Ar 代表芳香族基团，R'代表氢原子或饱和脂肪族基团，或 Ar 和 R1 可与它们所键合的碳原子一起形成缩合环；R2 代表氢原子、烷基或羟烷基。 其特征在于通式的α-磺酰氧基酮缩醛 其中 R3 和 R4 独立地代表一个烷基，或合在一起代表一个亚烷基；R5 代表一个取代或未取代的烷基或芳香基；Ar 和 R1 如上所定义。
• Synthesis and anticonvulsant activity of N-(benzoylalkyl)imidazoles and N-(.omega.-phenyl-.omega.-hydroxyalkyl)imidazoles
  作者：Dante Nardi、Alberto Tajana、Amedeo Leonardi、Renzo Pennini、Ferruccio Portioli、Maria Jose Magistretti、Alessandro Subissi

  DOI：10.1021/jm00138a017

  日期：1981.6

  A novel series of N-(benzoylalkyl)imidazoles and N-(omega-phenyl-omega-hydroxyalkyl)imidazoles was synthesized and evaluated for anticonvulsant activity in mice against maximal electroshock induced seizures. Some of the compounds showed an activity comparable to or better than phenytoin and phenobarbital. The N-[beta-[4-(beta-phenylethyl)phenyl]-beta-hydroxyethyl]imidazole (38) was selected for further studies; preclinical toxicology and additional efficacy evaluations are in progress. Structure-activity relationships are discussed.